The following baseline characteristics were positively associated with CEs (hereafter cardiac risk factors) for the entire population, after adjusting for confounding variable in the multivariate analysis: pre anti-HER2 treatment LVEF <55% (vs >64%, OR = 3.1; p = 0.002), diabetes mellitus (OR = 1.85; p = 0.002), BMI > 30 kg/m2 (vs <25 mg/kg2, OR = 2.21; p < 0.001), cumulative dose of doxorubicin ≥ 240 mg/m2 (OR = 1.36; p = 0.039) and cumulative dose of epirubicin ≥480 mg/m2 (OR = 2.33; p < 0.001) (Table 3). This evidence concerns the gene ERBB2 and diabetes mellitus.